Researchers examined data from 34 different studies, publishing their full systematic review and meta-analysis in JAMA Pediatrics.

As this new ablation technique continues to gain momentum, researchers are hoping to learn as much as possible about any potential side effects. 

After its initial release was limited to certain customers, the new-look catheter is now available in four different sizes throughout the United States.

LivaNova PLC developed the new cardio-pulmonary system based on feedback from more than 300 perfusionists.

Paul Sorajja, MD, discusses the late-breaking TRILUMINATE pivotal trial at ACC.23 and how tricuspid TEER performed against the current standard of care using medical therapy.

New research presented at the American College of Cardiology’s annual meeting has shown that long-term intermittent fasting improved outcomes for individuals with COVID-19 who also have a history of heart disease.

One key takeaway was that women faced a higher MI risk than men, but only for the first 30 days. 

The recommendations were developed by a writing group comprised of experts from different specialties, offering an array of perspectives and approaches.

Provention Bio's TZIELD is the first and only therapy to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D. 

The most recent updates contain “substantial new content and safety recommendations," the ACR reported recently.